Teva partners with Klinge Biopharma for marketing of Formycon biosimilar, positive for Formycon stock.

From GlobeNewswire: 2025-01-13 22:26:10

Klinge Biopharma GmbH (Klinge) has secured exclusive global marketing rights for FYB203, Formycon’s biosimilar candidate for Eylea. Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd., has entered into a strategic collaboration with Klinge and Formycon AG for the semi-exclusive marketing of FYB203 in Europe (excluding Italy) and Israel. Teva will lead the marketing efforts for FYB203, which is expected to be marketed as AHZANTIVE® pending regulatory approval. Formycon is a leading developer of high-quality biosimilars, with a focus on various therapeutic areas, including ophthalmology. The FDA approved FYB203 in June 2024, and a positive recommendation from the CHMP in November 2024 sets the stage for European Commission approval in early 2025. Eylea, a treatment for various serious eye conditions, generated approximately $9 billion in global sales in 2023, underscoring its importance in the anti-VEGF therapy market. Teva is committed to expanding access to high-quality, innovative medicines for the benefit of patients and healthcare systems. Formycon’s stock is listed on the Prime Standard of the Frankfurt Stock Exchange, and the company is focused on developing biosimilars to enhance patient access to effective and affordable medications.



Read more at GlobeNewswire: Teva gibt Zusammenarbeit zur Vermarktung des Formycon